Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 6/20 | 0.67 |
| ▸ | PIM1 | P11309 | 3/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | MAX | P61244 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449166 | 0.95 | NAT1 (0.74) | NAT1PIM1PDE4BPTP4A3MEN1 | |
| SCHEMBL18102942 | 0.81 | NAT1 (0.78) | NAT1PIM1PDE4BPTP4A3GSK3B | |
| SCHEMBL15421702 | 0.81 | NAT1 (1.00) | NAT1PIM1PTP4A3GSK3BCA2 | |
| SCHEMBL3425968 | 0.81 | NAT1 (1.00) | NAT1PIM1PTP4A3GSK3BCA2 | |
| SCHEMBL3425971 | 0.81 | NAT1 (1.00) | NAT1PIM1PTP4A3GSK3BCA2 | |
| SCHEMBL18102951 | 0.79 | NAT1 (0.74) | NAT1PIM1PDE4BPTP4A3GSK3B | |
| SCHEMBL18103030 | 0.79 | PDE4B (0.75) | NAT1PIM1PDE4BGSK3BCA2 | |
| SCHEMBL18102984 | 0.77 | NAT1 (0.59) | NAT1PIM1PDE4BPTP4A3GSK3B | |
| SCHEMBL18102954 | 0.77 | NAT1 (0.70) | NAT1PIM1PTP4A3CA2EPHX1 | |
| SCHEMBL18103072 | 0.76 | NAT1 (0.79) | NAT1PIM1PTP4A3GSK3BCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| US-20060264484-A1 | Fc receptor modulating compounds and compositions | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264484-A1 | Fc receptor modulating compounds and compositions | FCGR1A, FCGR2A, FCGR3B | NAT1 3116/4885PIM1 3443/4885PDE4B 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.